Related Experiment Video
Updated: May 24, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Pharmacogenetics of asthma controller treatment
E B Mougey1, C Chen, K G Tantisira
1ALA-Asthma Clinical Research Center, Jacksonville, FL, USA.
The Pharmacogenomics Journal
|February 29, 2012
Summary
This study identified novel genetic variants (SNPs) associated with how well asthma patients respond to common controllers like fluticasone and montelukast, paving the way for personalized asthma treatment.
Area of Science:
- Pharmacogenomics
- Asthma Therapeutics
- Genetic Association Studies
Background:
- Interpatient variability in asthma controller response is significant.
- This variability is linked to pharmacogenomic differences.
- Identifying genetic markers can help personalize asthma management.
Purpose of the Study:
- To identify novel single nucleotide polymorphisms (SNPs) associated with patient response to fluticasone, fluticasone + salmeterol, and montelukast.
- To investigate candidate genes in the β2-adrenergic receptor, corticosteroid, and leukotriene pathways.
- To explore the potential of genetic variants in tailoring asthma treatment strategies.
Main Methods:
- Genotyped 169 SNPs in 26 candidate genes in 189 Caucasian asthma patients.
- Assessed treatment response using Asthma Control Questionnaire (ACQ) scores and FEV1 changes over 16 weeks.
- Analyzed SNP-outcome associations using general linear models with corrections for multiple comparisons.
Main Results:
- Identified 16 significant SNPs in seven genes associated with treatment response.
- Found associations between CHRM2 SNPs and ACQ slope for fluticasone/salmeterol.
- Discovered CRHR1 and COL2A1 SNPs linked to fluticasone response, and CHRM2 SNPs associated with montelukast response, showing potential opposing effects.
Conclusions:
- Several novel SNPs significantly associate with responses to common asthma controllers.
- These findings support further pharmacogenomic research in asthma.
- Genetic variants hold promise for personalizing asthma pharmacotherapy.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...